CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for X4 Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

X4 Pharmaceuticals Inc
61 NORTH BEACON STREET, 4TH FLOOR
Phone: (857) 529-8300p:857 529-8300 BOSTON, MA  02134  United States Ticker: XFORXFOR
Business Summary
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Michael S.Wyzga 68 3/13/2019 3/13/2019
President, Chief Executive Officer, Secretary, Director PaulaRagan 53 7/1/2014 7/1/2014
Chief Financial Officer, Treasurer, Corporate Secretary Adam S.Mostafa 43 9/1/2022 9/1/2018
8 additional Officers and Directors records available in full report.

Business Names
Business Name
ASNS
X4 Pharamaceuticals(Austria) GmbH
X4 Pharmaceuticals Securities Corporation
X4 Pharmaceuticals, Inc.
X4 Therapeutics Inc.
XFOR

General Information
Number of Employees: 93 (As of 12/31/2023)
Outstanding Shares: 167,937,781 (As of 3/18/2024)
Shareholders: 60
Stock Exchange: NASD
Federal Tax Id: 273181608
Fax Number: (302) 655-5049
Email Address: info@arsanis.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024